U.S. Food and Drug Administration Commissioner Martin Makary said in a New York Times guest essay that Hims & Hers’ Super Bowl advertisement breached federal law as it highlighted the benefits of weight-loss drugs without mentioning side effects. “The FDA is taking action,” Makary said, adding that “Earlier this week, the agency sent approximately 100 cease-and-desist letters to pharmaceutical companies whose ads were found to violate the law. This includes several online pharmacies. The FDA also sent thousands of letters to companies warning them to remove ads that violate the law and alerting them to our new diligent enforcement posture going forward.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Time to Bet on Hims & Hers Health (HIMS)? Analysts Point to Several Growth Catalysts
- Hims & Hers Health Stock Surges Amid Mixed Analyst Views
- Cautious Outlook on Hims & Hers Health Amidst Regulatory Changes and Increased Volatility
- Sell Recommendation for Hims & Hers Health Due to Modest Revenue Expectations and High Marketing Costs
- Video: Advertising, drugmaker stocks in spotlight after Trump signs pharma order